Year: 2025

CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares (or common share equivalents in lieu thereof) in a registered direct offering (the “Offering”) at a purchase price of US$0.63 per common share. The closing of the Offering is expected to occur on or about October 22, 2025, subject to the satisfaction of customary closing conditions and approval from the TSX Venture Exchange. The gross proceeds from the Offering are expected to be US$1.1 million,...

Lassila & Tikanoja plcInvestor News21 October 2025 at 3.00 PM Invitation to  Lassila & Tikanoja’s Capital Markets Day on 26 November 2025 L&T has the pleasure of inviting analysts and investors to its Capital Markets Day in Helsinki, Finland, on Wednesday, 26 November 2025. The event will focus on New L&T and Luotea as separate businesses, and their further value creation potential following L&T’s Board of Directors’ decision to propose to separate New L&T as a new standalone listed company on or about 31 December 2025*.New L&T is positioned as a Circular Economy leader in the Nordics with multiple growth avenues identified for substantial value creation opportunities. Luotea is an established Nordic facility services player with an improved operating model geared for growth.The Capital Markets Day...

BRØNDBYERNES I.F. FODBOLD A/SCVR-nr. 83 93 34 10 Brøndby, den 21. oktober 2025 SELSKABSMEDDELELSE NR. 11/2025 Offentliggørelse af regnskabstal per 30. september 2025 I forbindelse med den ordinære generalforsamling den 21. oktober 2025 offentliggør Brøndbyernes I.F. Fodbold A/S udvalgte foreløbige, ikke-reviderede regnskabstal for 1. kvartal af regnskabsåret 2025/26, som dækker perioden 1. juli til 30. september 2025. Offentliggørelsen sker som en enkeltstående orientering til markedet og indebærer ikke en ændring i selskabets rapporteringspraksis. Brøndbyernes I.F. Fodbold A/S har ikke tidligere offentliggjort kvartalsregnskaber siden 2019 og har ikke planer om at offentliggøre kvartalsvise regnskabsrapporter fremover. Tallene præsenteres i nedenstående forkortede balanceopgørelse pr. 30. september 2025:Aktiver MDKK Passiver MDKK           Egenkapital 326       Immaterielle...

Bagsværd, Denmark, 21 October 2025 – Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk. “Following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors, it has not been possible to reach a common understanding. The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration. After thorough deliberation and considering the Foundation’s position and control of the majority of votes in Novo Nordisk, the Board concluded that it is in the best interest of the company and its shareholders to convene an Extraordinary General Meeting to elect...

RDA Agreement establishes framework for a cooperative, mutually beneficial and respectful relationship between Discovery and TTN TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company and Taykwa Tagamou Nation (“TTN”) have entered into a Resource Development Agreement (“RDA”). The RDA is intended to establish a framework for ongoing consultation and communication for the purpose of establishing a cooperative, mutually beneficial and respectful relationship between the parties and provide a basis for support of Discovery’s mining and mineral processing activities within TTN’s traditional territory. Tony Makuch, Discovery’s CEO, commented: “We are honored to have entered into this agreement with TTN and wish to thank the band council...

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)  Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University have now joined BriaCell’s extensive national networkPHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the addition of several key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612), notably Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University....

Mikra product lineup features new formulations and fresh branding at accessible prices to attract U.S. consumers and drive sustainable growth TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSX.V: LFST; OTCQB: LFSWF; FRANKFURT: M5B0) announces the return of its Mikra brand to Amazon.com in the United States with a lineup featuring new performance-based products, refreshed formulations and attractive packaging designed to elevate customer engagement. The new Mikra storefront can be found here. “We’re making it easier for U.S. consumers to discover and shop Mikra’s growing portfolio of performance-enhancing products,” said Andrea Judge, CEO of Lifeist. “Our revitalized brand and expanded portfolio of innovative formulations are shaped by consumer insights and market learnings. We’re also...

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). To date, six patients have been successfully enrolled into the trial, Of these, two patients were enrolled at Johns Hopkins University School of Medicine and four at Yale School of Medicine’s Department of Psychiatry. The multinational, multicenter Phase I/IIa trial is designed as a single- and multiple-dose...